临床试验设计与结果传播:2005年以来clinicaltrials.gov与PubMed数据的综合分析
研究发现产业资助者更倾向开展大型国际随机对照试验,且结果公开率高于非营利资助者,传播方式与疾病领域亦存在差异。
要点
- 产业资助试验结果公开率59.3%,高于非营利资助的45.3%。
- 大型药企试验结果公开率66.7%,高于小型药企的45.2%。
- 随机对照试验的期刊发表率34.9%,高于非随机研究的18.2%。
核心结论
- 临床试验设计与结果传播因资助机构类型、规模及疾病领域不同而存在显著差异。
主要发现
- 产业资助者比非营利资助者更可能资助大型国际随机对照试验,但方法学差异随时间缩小。
- NIH资助试验结果公开率为60.0%(1451/2417),其他非营利机构为40.6%(3104/7649)。
临床怎么用
- 关注不同资助来源试验的结果公开情况,评估证据可及性时需考虑资助类型与疾病领域差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the distribution, design characteristics, and dissemination of clinical trials by funding organisation and medical specialty. DESIGN: Cross sectional descriptive analysis. DATA SOURCES: Trial protocol information from clinicaltrials.gov, metadata of journal articles in which trial results were published (PubMed), and quality metrics of associated journals from SCImago Journal and Country Rank database. SELECTION CRITERIA: All 45 620 clinical trials evaluating small molecule therapeutics, biological drugs, adjuvants, and vaccines, completed after January 2006 and before July 2015, including randomised controlled trials and non-randomised studies across all clinical phases. RESULTS: Industry was more likely than non-profit funders to fund large international randomised controlled trials, although methodological differences have been decreasing with time. Among 27 835 completed efficacy trials (phase II-IV), 15 084 (54.2%) had disclosed their findings publicly. Industry was more likely than non-profit trial funders to disseminate trial results (59.3% (10 444/17 627) v 45.3% (4555/10 066)), and large drug companies had higher disclosure rates than small ones (66.7% (7681/11 508) v 45.2% (2763/6119)). Trials funded by the National Institutes of Health (NIH) were disseminated more often than those of other non-profit institutions (60.0% (1451/2417) v 40.6% (3104/7649)). Results of studies funded by large drug companies and NIH were more likely to appear on clinicaltrials.gov than were those from non-profit funders, which were published mainly as journal articles. Trials reporting the use of randomisation were more likely than non-randomised studies to be published in a journal article (6895/19 711 (34.9%) v 1408/7748 (18.2%)), and journal publication rates varied across disease areas, ranging from 42% for autoimmune diseases to 20% for oncology. CONCLUSIONS: Trial design and dissemination of results vary substantially depending on the type and size of funding institution as well as the disease area under study.
引用
- Zwierzyna M, Davies M, Hingorani AD, et al. Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005. BMJ. 2018. PMID: 29875212. doi:10.1136/bmj.k2130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。